Latest Breaking News On - Severe plaque - Page 1 : comparemela.com

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomPuerto ricoSan diegoFrance generalJessica akopyanJustin claeysKate meyerLoretta fiorilloCallis duffinPonda motsepe ditshegoMelinda gooderhamJolla institute for immunologyChemocentryx incTeneobio incAmerican academy of dermatology

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
bubblear.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bubblear.com Daily Mail and Mail on Sunday newspapers.

United statesPuerto ricoUnited kingdomSan diegoFrance generalJessica akopyanLoretta fiorilloMelinda gooderhamKate meyerCallis duffinPonda motsepe ditshegoJustin claeysAmerican academy of dermatologyDrug administrationWorld best companiesNational psoriasis foundation

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024

AMGEN PRESENTS NEW RESEARCH ON OTEZLA® (APREMILAST) AT AAD 2024
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Puerto ricoUnited kingdomUnited statesFrance generalSan diegoMelinda gooderhamLoretta fiorilloJessica akopyanPonda motsepe ditshegoCallis duffinKate meyerJustin claeysJolla institute for immunologyNational psoriasis foundationTeneobio incAmerican academy of dermatology

Tremfya outperforms IL-17 inhibitors in treatment persistence for plaque psoriasis

Tremfya demonstrated greater treatment persistence than interleukin-17 inhibitors in patients with moderate to severe plaque psoriasis and achieved clinical efficacy in scalp psoriasis, according to data presented here.Tremfya (guselkumab, Janssen Biotech) is the first and only fully human selective interleukin (IL)-23 approved in the United States for adults with moderate to severe plaque

United statesSteven feldmanBygabrielle capaldoKristen dowdAmerican academy of dermatology annual meetingWake forest university school of medicineAmerican academyDermatology annual meetingJanssen biotechDermatology annualWake forest university schoolBoth bio naBio experienced patients living with moderateSevere plaquePublished march

Dermavant Sciences, Inc : Dermavant to Present Data from Multiple Studies of VTAMA (tapinarof) cream, 1% at the 2023 Winter Clinical Dermatology Conference

- Seven posters will include clinical data for VTAMA cream for the treatment of plaque psoriasis in adults and atopic dermatitis (AD), including data from the successful pediatric maximum usage study

United statesLaurence wattsChristopherem griffithsHolly gloverStephenc piscitelliPhilipm brownKimberly mchaleMarkg lebwohlAprilw armstrongShawng kwatraKima pappBruce stroberRachaela clarkScott guenthnerMatthewj brunoAnnam tallman